Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update

(2018) M. Maurer et al.   ALLERGY

Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years

(2018) Henriette Farkas et al.   Expert Review of Clinical Immunology

Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema

(2017) Henriette Farkas et al.   Journal of Allergy and Clinical Immunology-In Practice

Icatibant as acute treatment for hereditary angioedema in adults

(2016) Henriette Farkas   Expert Review of Clinical Pharmacology

Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial

(2014) A. Malbrán et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial

(2011) William R. Lumry et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema

(2010) Marco Cicardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-Like Peptide-2 Analog in Neonates and Infants With Short-Bowel Syndrome

(2009) M S Mouksassi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Icatibant

(2009) Emma D. Deeks   DRUGS